PillSense System
DeviceThe PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
NCT Number: NCT05631639
This is a multi-center, prospective, non-randomized, open-label, exploratory clinical investigation performed to evaluate safety and effectiveness of the PillSense System when used for detection of blood in the stomach of patients suspected to have an Upper Gastrointestinal Bleed (UGIB).
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Fakultní nemocnice Olomouc (FNOL), Olomouc, Czechia
The PillSense System consists of the PillSense Capsule, an atraumatic, ingestible, and disposable capsule and PillSense Receiver, an external real-time monitor for results display. The PillSense Capsule is a non-invasive, single use device designed to detect blood in the stomach and wirelessly transmit the data to the external PillSense Receiver. The receiver is a handheld device which displays real-time information gathered from the capsule and clearly displays results, "Blood Detected" or "No Blood Detected".
All enrolled participants were admitted for suspected UGIB and were required to ingest a PillSense Capsule followed by esophagogastroduodenoscopy (EGD) within 1 hour of PillSense Capsule administration. All Patients underwent standard endoscopy following PillSense Capsule evaluation and results were compared with the PillSense System result, i.e., "Blood Detected" or "No Blood Detected".
The study was also designed to confirm transit of the PillSense Capsule through the GI tract and patient tolerability of the PillSense Capsule.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
Time frame: within 30 minutes
Ability of PillSense Capsule to detect the presence or absence of blood and send the results to the PillSense receiver
Time frame: within 2 hours
Subjects with positive findings for blood based on PillSense and EGD
Time frame: within 2 hours
Subjects with negative findings for blood based on PillSense and EGD
Time frame: up to 3 weeks
Number of patients that developed device-related adverse event (etc. retention, aspiration or bowel obstruction)
EnteraSense Limited
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06077916
Digestive System Diseases, Gastrointestinal Diseases
Bucharest, Romania
View Trial DetailsNCT06350864
Digestive System Diseases, Gastrointestinal Diseases
Cairo, Egypt
View Trial DetailsNCT06297954
Digestive System Diseases, Gastrointestinal Diseases
Monterrey, Nuevo León, Mexico
View Trial DetailsNCT04472364
Digestive System Diseases, Gastrointestinal Diseases
Berlin, Germany
View Trial Details